448 related articles for article (PubMed ID: 37888583)
21. The Functional Roles of Immune Cells in Primary Liver Cancer.
Pham L; Kyritsi K; Zhou T; Ceci L; Baiocchi L; Kennedy L; Chakraborty S; Glaser S; Francis H; Alpini G; Sato K
Am J Pathol; 2022 Jun; 192(6):826-836. PubMed ID: 35337836
[TBL] [Abstract][Full Text] [Related]
22. The role of tumour microenvironment: a new vision for cholangiocarcinoma.
Chen Z; Guo P; Xie X; Yu H; Wang Y; Chen G
J Cell Mol Med; 2019 Jan; 23(1):59-69. PubMed ID: 30394682
[TBL] [Abstract][Full Text] [Related]
23. Integrated pan-cancer analysis of centromere protein F and experimental verification of its role and clinical significance in cholangiocarcinoma.
Cao Z; Zeng L; Wang Z; Wen X; Zhang J
Funct Integr Genomics; 2023 May; 23(2):190. PubMed ID: 37247093
[TBL] [Abstract][Full Text] [Related]
24. Any Role for Microbiota in Cholangiocarcinoma? A Comprehensive Review.
Elvevi A; Laffusa A; Gallo C; Invernizzi P; Massironi S
Cells; 2023 Jan; 12(3):. PubMed ID: 36766711
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
26. Immunology and immunotherapy of cholangiocarcinoma.
Greten TF; Schwabe R; Bardeesy N; Ma L; Goyal L; Kelley RK; Wang XW
Nat Rev Gastroenterol Hepatol; 2023 Jun; 20(6):349-365. PubMed ID: 36697706
[TBL] [Abstract][Full Text] [Related]
27. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma.
Loeuillard E; Yang J; Buckarma E; Wang J; Liu Y; Conboy C; Pavelko KD; Li Y; O'Brien D; Wang C; Graham RP; Smoot RL; Dong H; Ilyas S
J Clin Invest; 2020 Oct; 130(10):5380-5396. PubMed ID: 32663198
[TBL] [Abstract][Full Text] [Related]
28. Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma.
Alnaggar M; Xu Y; Li J; He J; Chen J; Li M; Wu Q; Lin L; Liang Y; Wang X; Li J; Hu Y; Chen Y; Xu K; Wu Y; Yin Z
J Immunother Cancer; 2019 Feb; 7(1):36. PubMed ID: 30736852
[TBL] [Abstract][Full Text] [Related]
29. An Insight into Cholangiocarcinoma and Recent Advances in its Treatment.
Sahu R; Sharma P; Kumar A
J Gastrointest Cancer; 2023 Mar; 54(1):213-226. PubMed ID: 35023010
[TBL] [Abstract][Full Text] [Related]
30. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.
Wu HJ; Chu PY
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710
[TBL] [Abstract][Full Text] [Related]
31. Proteogenomic characterization of cholangiocarcinoma.
Deng M; Ran P; Chen L; Wang Y; Yu Z; Cai K; Feng J; Qin Z; Yin Y; Tan S; Liu Y; Xu C; Shi G; Ji Y; Zhao JY; Zhou J; Fan J; Hou Y; Ding C
Hepatology; 2023 Feb; 77(2):411-429. PubMed ID: 35716043
[TBL] [Abstract][Full Text] [Related]
32. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.
Louis C; Edeline J; Coulouarn C
Expert Opin Ther Targets; 2021 Feb; 25(2):153-162. PubMed ID: 33502260
[No Abstract] [Full Text] [Related]
33. Immune checkpoint inhibitors and combinations with other agents in cholangiocarcinoma.
Skouteris N; Papageorgiou G; Fioretzaki R; Schizas D; Kykalos S; Tolia M; Charalampakis N
Immunotherapy; 2023 May; 15(7):487-502. PubMed ID: 36876442
[TBL] [Abstract][Full Text] [Related]
34. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma.
Tomlinson JL; Li B; Yang J; Loeuillard E; Stumpf HE; Kuipers H; Watkins R; Carlson DM; Willhite J; O'Brien DR; Graham RP; Chen X; Smoot RL; Dong H; Gores GJ; Ilyas SI
J Hepatol; 2024 Jun; 80(6):892-903. PubMed ID: 38458319
[TBL] [Abstract][Full Text] [Related]
35. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
Banales JM; Cardinale V; Carpino G; Marzioni M; Andersen JB; Invernizzi P; Lind GE; Folseraas T; Forbes SJ; Fouassier L; Geier A; Calvisi DF; Mertens JC; Trauner M; Benedetti A; Maroni L; Vaquero J; Macias RI; Raggi C; Perugorria MJ; Gaudio E; Boberg KM; Marin JJ; Alvaro D
Nat Rev Gastroenterol Hepatol; 2016 May; 13(5):261-80. PubMed ID: 27095655
[TBL] [Abstract][Full Text] [Related]
36. Future directions in the treatment of cholangiocarcinoma.
Zhu AX
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies.
Argemi J; Ponz-Sarvise M; Sangro B
Adv Cancer Res; 2022; 156():367-413. PubMed ID: 35961706
[TBL] [Abstract][Full Text] [Related]
38. Cancer-associated fibroblasts in cholangiocarcinoma.
Vaquero J; Aoudjehane L; Fouassier L
Curr Opin Gastroenterol; 2020 Mar; 36(2):63-69. PubMed ID: 31934895
[TBL] [Abstract][Full Text] [Related]
39. Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma.
Høgdall D; Lewinska M; Andersen JB
Trends Cancer; 2018 Mar; 4(3):239-255. PubMed ID: 29506673
[TBL] [Abstract][Full Text] [Related]
40. Immunosuppressive tumor microenvironment in occupational cholangiocarcinoma: Supportive evidence for the efficacy of immune checkpoint inhibitor therapy.
Sato Y; Tanaka S; Kinoshita M; Takemura S; Shinkawa H; Kokudo T; Hasegawa K; Tanaka H; Yoshimoto H; Mori A; Yamamura M; Sasaki M; Harada K; Kubo S
J Hepatobiliary Pancreat Sci; 2020 Nov; 27(11):860-869. PubMed ID: 32506715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
